Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIc Study

Diabetes Therapy

Volumn 7, Issue 2, 2016, Pages 349-360

  Matsuba, Ikuro ^a   Sawa, Tasuku ^b   Kawata, Takehiro ^a   Kanamori, Akira ^a   Jiang, Dingfeng ^c   Machimura, Hideo ^a   Takeda, Hiroshi ^a   Han, Jeong Hee ^d   Wang, Ke ^e   Tanaka, Keiji ^a   Shen, Li ^e   Ajima, Miho ^f   Kaneshiro, Mizuki ^a   Kim, Sang Wook ^g   Umezawa, Shinichi ^a   Asakura, Taro ^a   Suzuki, Shuichi ^c   Kim, Seoyoung C ^h,i  

^a Kanagawa Health Service Association   (Japan)

^b KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^c ELI LILLY AND COMPANY   (United States)

^d Lilly Korea   (South Korea)

^e Lilly Suzhou Pharmaceutical Co   (China)

^f Kawasaki Saiwai Clinic   (Japan)

^g Kangwon National University   (South Korea)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Asia; Diabetes Mellitus; Hypoglycemia; Insulin; Patient reported outcomes; Type 2

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CHINA; COMORBIDITY ASSESSMENT; DIABETES DISTRESS SCALE; DISEASE ASSOCIATION; DISEASE DURATION; DISTRESS SYNDROME; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; JAPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SOUTH KOREA;

EID: 84975873910     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-016-0178-7     Document Type: Article

References (37)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
2. Wang W, McGreevey WP, Fu C, Zhan S, Luan R, Chen W, et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care. 2009;15:593–601.
3. International Diabetes Federation. IDF Diabetes Atlas: Sixth Edition. International Diabetes Federation Brussels, Belgium. Available at http://www.idf.org/diabetesatlas. Accessed May 20, 2015.
4. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.
5. Shim YT, Lee J, Toh MP, Tang WE, Ko Y. Health-related quality of life and glycaemic control in patients with Type 2 diabetes mellitus in Singapore. Diabet Med. 2012;29:e241–8.
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
7. Japan Diabetes Society. Treatment Guide for Diabetes 2012–2013. http://www.jds.or.jp/modules/en/index.php?content_id=1. Accessed Apr 1, 2015.
8. Chinese Diabetes Society. China guideline for type 2. Diabetes. 2013;2014(6):447–98.
9. Korean Diabetes Association. Korean Diabetes Research Foundation, and International Conference on Diabetes and Metabolism 2013. Diabetes Fact Sheet in Korea 2013. http://www.diabetes.or.kr/english/. Accessed Apr 10, 2015.
10. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29:e13–20.
11. Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011;37:111–23.
12. Patrick AR, Fischer MA, Choudhry NK, Shrank WH, Seeger JD, Liu J, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2014;29:320–7.
13. Polinski JM, Curtis BH, Seeger JD, Choudhry NK, Zagar A, Shrank WH. Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study. BMC Endocr Disord. 2012;12:20.
14. Tan AM, Muthusamy L, Ng CC, Phoon KY, Ow JH, Tan NC. Initiation of insulin for type 2 diabetes mellitus patients: what are the issues? A qualitative study. Singap Med J. 2011;52:801–9.
15. Wong S, Lee J, Ko Y, Chong MF, Lam CK, Tang WE. Perceptions of insulin therapy amongst Asian patients with diabetes in Singapore. Diabet Med. 2011;28:206–11.
16. Polinski JM, Smith BF, Curtis BH, Seeger JD, Choudhry NK, Connolly JG, et al. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ. 2013;39:53–65.
17. Ishii H, Terauchi Y, Jinnouchi H, Taketsuna M, Takeuchi M, Imaoka T. Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: the insulin-changing study intending to gain patients’ insights into insulin treatment with patient-reported health outcomes in actual clinical treatments (INSIGHTs) study. J Diabetes Investig. 2013;4:560–70.
18. Polinski JM, Connolly JG, Curtis BH, Seeger JD, Gaskins K, Perez M, et al. Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review. Prim Care Diabetes. 2014;8:101–9.
19. Polinski JM, Kim SC, Jiang D, Hassoun A, Shrank WH, Cos X, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocr Disord. 2015;15:46.
20. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28:626–31.
21. Fitzgerald JT, Funnell MM, Hess GE, Barr PA, Anderson RM, Hiss RG, et al. The reliability and validity of a brief diabetes knowledge test. Diabetes Care. 1998;21:706–10.
22. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–94.
23. Ji L, Su Q, et al. Glycemic control and self-monitoring of blood glucose in Chinese patients with type 2 diabetes on insulin: baseline results from the COMPASS study. Diabetes Res Clin Pract. 2016;112:82–7.
24. Ji L, Zhang P, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled by oral hypoglycemic agents in china-study design and baseline characteristics. Diabetes Technol Ther. 2015;17(10):735–44.
25. Kanatsuka A, Kawai K, Hirao K, Yokoyama H, Kobayashi M. The initiation of insulin therapy in type 2 diabetic patients treated with oral anti-diabetic drugs: an observational study in multiple institutes across Japan (JDDM27). Diabetol Int. 2012;3:164–73.
26. Kim SS, Kim IJ, Kim YK, Yoon KH, Son HY, Park SW, et al. Duration of diabetes and effectiveness of insulin in the management of insulin-naive Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MOdaliTy of Insulin treatment eValuation (MOTIV) registry results. Acta Diabetol. 2014;51:655–61.
27. Yang W, Lu J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.
28. Charvat H, Goto A, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig. 2015;6(5):533–42.
29. Korean Diabetes Association. Korean Diabetes Fact Sheet 2015 Edition. http://www.diabetes.or.kr/temp/KDA_fact_sheet%202015.pdf. Accessed Apr 28, 2016.
30. Tsai ST, Pathan F, Ji L, Yeung VT, Chadha M, Suastika K, et al. First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3:208–16.
31. Korean Diabetes Association. Korean Diabetes Association Guidelines 2013.
32. National Development and Reform Commission of the People’s Republic of China. Notification Number [2012]4134: Maximum Retail Pricing of Drugs. http://www.ndrc.gov.cn/zwfwzx/zfdj/jggg/yaopin/201301/W020130121540619076885.pdf. Accessed Apr 13, 2015.
33. National Health and Family Planning Commission of the People’s Republic of China. National essential drug list (2012 edition). http://www.sdpc.gov.cn/zcfb/zcfbtz/201301/W020130110304201259649.pdf. Accessed Oct 2, 2015.
34. Yang J, Li J. Premixed or basal insulin: the insulin initiation consideration in Chinese patients with type 2 diabetes mellitus. Chin J Endocrinol Metab. 2013;29(5):5b–1.
35. Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, Komuro I, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54:93–7.
36. Zagarins SE, Allen NA, Garb JL, Welch G. Improvement in glycemic control following a diabetes education intervention is associated with change in diabetes distress but not change in depressive symptoms. J Behav Med. 2012;35:299–304.
37. Wardian J, Sun F. Factors associated with diabetes-related distress: implications for diabetes self-management. Soc Work Health Care. 2014;53:364–81.